2.4 Central Nervous System & Pain Management

Central Nervous System & Pain Management

The central nervous system (CNS) therapeutic area involves drugs with profound physiological effects, significant abuse potential, and narrow therapeutic indices. Pharmacists are the ultimate gatekeepers for controlled substances, possessing a corresponding responsibility to ensure prescriptions are written for a legitimate medical purpose. Managing pain involves strict adherence to CDC guidelines and California state laws regarding opioid prescribing, naloxone furnishing, and detecting prescription abuse. Furthermore, managing psychiatric and neurological conditions requires a deep understanding of pharmacokinetics, therapeutic drug monitoring, and complex drug-drug interactions.

1. Opioid Pain Management and MME Calculations

The opioid epidemic has led to stringent regulatory frameworks. The CDC guidelines emphasize that opioids are not first-line therapy for chronic non-cancer pain; non-pharmacologic and non-opioid pharmacologic therapy (NSAIDs, acetaminophen, SNRIs, gabapentinoids) are preferred. When opioids are required, they must be prescribed at the lowest effective dose for the shortest possible duration.

Morphine Milligram Equivalents (MME)

To standardize the assessment of overdose risk, all opioid regimens must be converted to Morphine Milligram Equivalents (MME) per day. High dosages (≥ 50 MME/day) warrant careful reassessment, and dosages ≥ 90 MME/day should generally be avoided or require a pain specialist consultation.

Common MME Conversion Factors:

• Hydrocodone: 1
• Oxycodone: 1.5
• Oxymorphone: 3
• Hydromorphone: 4
• Fentanyl transdermal (mcg/hr): approx. 2.4 (Note: varies by chart, but fentanyl is extremely potent)

Calculation Example: A patient is taking Oxycodone 15 mg every 6 hours and Hydromorphone 2 mg every 8 hours.

1. Total daily Oxycodone = 15 mg x 4 = 60 mg. MME = 60 x 1.5 = 90 MME.
2. Total daily Hydromorphone = 2 mg x 3 = 6 mg. MME = 6 x 4 = 24 MME.
3. Total daily MME = 90 + 24 = 114 MME/day. This patient is at exceptionally high risk for an overdose.

California Law and Naloxone Co-prescribing

Under California law, prescribers are legally required to offer a prescription for naloxone to the patient if:

1. The prescription dosage is ≥ 90 MME/day.
2. An opioid is prescribed concurrently with a benzodiazepine.
3. The patient presents with an increased risk for overdose (e.g., history of substance use disorder). Additionally, California pharmacists are authorized to independently furnish naloxone without a prescription under a state protocol. Pharmacists must provide mandatory counseling on overdose recognition, the importance of calling 911, and how to administer the naloxone (intranasal spray or intramuscular injection).

2. Benzodiazepines and Sedative-Hypnotics

Benzodiazepines (e.g., alprazolam, clonazepam, diazepam, lorazepam) potentiate GABA, the primary inhibitory neurotransmitter in the CNS. They are used for anxiety, panic disorders, seizures, and alcohol withdrawal.

Tapering and Withdrawal: Abrupt discontinuation of benzodiazepines after chronic use can lead to a severe, life-threatening withdrawal syndrome characterized by autonomic hyperactivity, delirium tremens, and status epilepticus (continuous seizures). Tapering must be done excruciatingly slowly, often over several months, sometimes switching to a long-acting agent like diazepam to ensure a smooth reduction in serum levels.

Black Box Warning: The FDA mandates a severe warning against the concurrent use of benzodiazepines and opioids, which results in profound respiratory depression, coma, and death. If combination therapy is clinically unavoidable, doses must be minimized, and naloxone must be co-prescribed.

3. Antiepileptic Drugs (AEDs)

Seizure management relies on AEDs, many of which are potent enzyme inducers or inhibitors and have narrow therapeutic ranges.

Phenytoin (Dilantin)

Phenytoin exhibits Michaelis-Menten (non-linear) pharmacokinetics. At low doses, it follows first-order kinetics; however, once the metabolic enzymes become saturated, even a small increase in dose can cause a massive, disproportionate spike in serum concentration, leading to severe toxicity (nystagmus, ataxia, diplopia, lethargy).

Phenytoin is highly protein-bound (90%) to albumin. The standard therapeutic range is 10-20 mcg/mL, representing total phenytoin (both bound and unbound). If a patient has low albumin (< 3.2 g/dL), there is more free, active drug in the blood, but the total measured level may appear artificially low or normal. The pharmacist must use the Corrected Phenytoin Formula:

Corrected Phenytoin = Measured Total Phenytoin / [(0.2 x Albumin) + 0.1] (Note: For patients with end-stage renal disease, the 0.2 factor changes to 0.1). If the corrected level exceeds 20 mcg/mL, the patient is toxic despite a seemingly normal total lab value.

Other Notable AEDs

• Valproic Acid (Depakote): Broad-spectrum AED. Carries black box warnings for fatal hepatotoxicity, pancreatitis, and severe teratogenicity (neural tube defects).
• Carbamazepine (Tegretol): Potent auto-inducer (induces its own metabolism). Can cause fatal dermatologic reactions (Stevens-Johnson Syndrome, SJS). HLA-B*1502 screening is required for patients of Asian descent prior to initiation.
• Lamotrigine (Lamictal): Highest risk of SJS. Must be titrated extremely slowly over several weeks using specific starter kits based on interacting medications (e.g., valproic acid inhibits lamotrigine metabolism, requiring a lower dose starter kit).

4. Psychotropics and Lithium

Antidepressants (SSRIs, SNRIs)

All antidepressants carry a Black Box Warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24). It takes 4-8 weeks for a full clinical effect. Abrupt discontinuation can lead to serotonin withdrawal syndrome.

Lithium

Lithium is the gold standard mood stabilizer for bipolar disorder. It has a very narrow therapeutic index (0.6 - 1.2 mEq/L). Because lithium is a monovalent cation handled by the kidneys identically to sodium, any change in sodium or fluid balance drastically affects lithium levels.

• Decreased Sodium (e.g., sweating, low-salt diet, ACE inhibitors, NSAIDs, thiazide diuretics) causes the kidneys to aggressively reabsorb sodium. The kidneys cannot distinguish lithium from sodium, leading to massive lithium reabsorption and fatal toxicity (ataxia, coarse tremors, arrhythmias, seizures).
• Increased Sodium or Fluid (e.g., high-salt diet, caffeine) leads to increased lithium clearance and subtherapeutic levels, risking a manic episode. Pharmacists must rigorously counsel patients to maintain a consistent salt and fluid intake and monitor renal and thyroid function, as long-term lithium use causes hypothyroidism and nephrogenic diabetes insipidus.